Research programme: antithrombotic agents - MediciNova

Drug Profile

Research programme: antithrombotic agents - MediciNova

Alternative Names: MN-447; MN-462

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Meiji Seika Kaisha
  • Developer MediciNova
  • Class Small molecules
  • Mechanism of Action Enzyme inhibitors; GPIIb-IIIa antagonists; Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Thrombosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombosis in USA
  • 09 Aug 2012 MN 447 and MN 462 are still in Preclinical trials for Thrombosis in USA
  • 01 Apr 2011 Meiji Seika Kaisha is now called Meiji Seika Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top